EPFL .NeuroRestore team expands enrollment criteria for spinal stimulation study

The team announced relaxed enrollment criteria to include patients with longer injury duration, testing therapy applicability across different disease stages.

博睿康癫痫监测电极多中心临床研究入组过半

Neuracle epilepsy monitoring electrode multicenter study passes halfway enrollment

The study evaluates the precision of a new cortical electrode in localizing epileptogenic foci; enrollment has passed the halfway mark, with completion expected within the year.

强脑科技康复训练系统真实世界数据观察研究启动

BrainCo launches real-world evidence study for rehabilitation training system

The study targets existing users of the already-marketed consumer rehabilitation product, collecting long-term usage data to support future indication expansion.

Blackrock Neurotech MoveAgain trial expands to third clinical site

The trial evaluates the companys neural interface system in assisting paralyzed patients with daily tasks; the new site is expected to accelerate enrollment.

阶梯医疗运动功能重建研究完成阶段性总结

StairMed motor function restoration study completes interim summary

The team disclosed interim data showing participants completing simple robotic arm tasks via the device, with plans to expand the sample size.

脑虎科技语言解码研究者发起临床研究进展通报

NeuroXess investigator-initiated speech decoding study progress update

The investigator-initiated study, run jointly with domestic hospitals, has completed several implants using flexible cortical electrodes for real-time text decoding.

Onward Medical Empower BCI trial completes first implant

The trial evaluates BCI combined with spinal cord stimulation for upper-limb recovery in spinal cord injury patients; the first procedure was completed in the Netherlands.

Precision Neuroscience Layer 7 array enters pivotal-stage clinical study

Following the 30-day implantation clearance, the company announced the launch of a pivotal-stage study targeting motor function restoration.

Neuralink PRIME study interim safety report

The report discloses electrode channel attrition among early participants; most channels remained stable while a minority showed gradual signal degradation.

Synchron COMMAND pivotal trial two-year follow-up results published

Data showed no device-related serious adverse events across participants, with functional usage metrics improving further from the early feasibility stage.